Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Summary

This is a multicenter, open-label study to assess the PK of a single 1-mg oral dose of CC-220 in subjects with mild, moderate, and severe hepatic impairment, and in matched healthy control subjects with normal hepatic function. Degree of hepatic impairment will be determined during the Screening period by the subject's score according to Child-Pugh Classification Criteria

Timeline

Start

2019-02-13

Primary completion

2019-06-18

Completion

2019-06-18

Drugs

Indications

No indication recorded.